JP2020508292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508292A5 JP2020508292A5 JP2019542544A JP2019542544A JP2020508292A5 JP 2020508292 A5 JP2020508292 A5 JP 2020508292A5 JP 2019542544 A JP2019542544 A JP 2019542544A JP 2019542544 A JP2019542544 A JP 2019542544A JP 2020508292 A5 JP2020508292 A5 JP 2020508292A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- therapy
- treatment
- trop
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463316P | 2017-02-24 | 2017-02-24 | |
| US62/463,316 | 2017-02-24 | ||
| US15/820,708 US10413539B2 (en) | 2012-12-13 | 2017-11-22 | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| US15/820,708 | 2017-11-22 | ||
| PCT/US2018/019025 WO2018156634A1 (en) | 2017-02-24 | 2018-02-21 | Therapy of small-cell lung cancer (sclc) with a topoisomerase-i inhibiting antibody-drug conjugate (adc) targeting trop-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508292A JP2020508292A (ja) | 2020-03-19 |
| JP2020508292A5 true JP2020508292A5 (https=) | 2020-10-15 |
| JP7188837B2 JP7188837B2 (ja) | 2022-12-13 |
Family
ID=63253429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542544A Active JP7188837B2 (ja) | 2017-02-24 | 2018-02-21 | Ｔｒｏｐ－２を標的化するトポイソメラーゼ－ｉ阻害抗体－薬物コンジュゲート（ａｄｃ）による小細胞肺癌（ｓｃｌｃ）の療法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3585442B1 (https=) |
| JP (1) | JP7188837B2 (https=) |
| CN (1) | CN110392580A (https=) |
| CA (1) | CA3043766A1 (https=) |
| ES (1) | ES2966466T3 (https=) |
| PL (1) | PL3585442T3 (https=) |
| RU (1) | RU2019124477A (https=) |
| WO (1) | WO2018156634A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115052632B (zh) * | 2020-01-15 | 2025-01-14 | 北京海步医药科技有限公司 | 靶向多肽-药物缀合物及其用途 |
| JP7673255B2 (ja) * | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| CN114288265B (zh) * | 2021-11-24 | 2026-03-31 | 宁波市第一医院 | 一种包含顺铂-亚油酸和sn38-亚油酸的纳米颗粒、制备方法及应用 |
| WO2023208341A1 (en) | 2022-04-27 | 2023-11-02 | ITM Isotope Technologies Munich SE | Combination treatment of small-cell lung cancer |
| CN117180447A (zh) * | 2023-04-23 | 2023-12-08 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Immu-132在制备用于治疗结直肠癌药物中的应用 |
| CA3221834A1 (en) * | 2023-06-30 | 2025-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Combination therapies for the treatment of non-small cell lung cancer |
| WO2025199464A1 (en) * | 2024-03-22 | 2025-09-25 | Eisai R&D Management Co., Ltd. | Anti-trop2 antibody-drug conjugates and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9770517B2 (en) * | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US20130029909A1 (en) * | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
| US10137196B2 (en) * | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US9492566B2 (en) * | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2016172427A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| EP4257134A3 (en) | 2015-06-25 | 2024-01-24 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
-
2018
- 2018-02-21 JP JP2019542544A patent/JP7188837B2/ja active Active
- 2018-02-21 CA CA3043766A patent/CA3043766A1/en active Pending
- 2018-02-21 ES ES18758120T patent/ES2966466T3/es active Active
- 2018-02-21 RU RU2019124477A patent/RU2019124477A/ru unknown
- 2018-02-21 WO PCT/US2018/019025 patent/WO2018156634A1/en not_active Ceased
- 2018-02-21 CN CN201880017528.6A patent/CN110392580A/zh active Pending
- 2018-02-21 PL PL18758120.2T patent/PL3585442T3/pl unknown
- 2018-02-21 EP EP18758120.2A patent/EP3585442B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508292A5 (https=) | ||
| Lai et al. | Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics | |
| JP2020512314A5 (https=) | ||
| RU2019126562A (ru) | ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51 | |
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| Rothenberg | Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond | |
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| Arend et al. | Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease | |
| Han et al. | In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma | |
| Perdrizet et al. | The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer | |
| CN105873440A (zh) | 适用于治疗癌症的用于抑制tie2激酶的方法 | |
| RU2019124477A (ru) | Терапия мелкоклеточного рака легких (мкрл) с помощью конъюгата антитело-лекарственный препарат (кап), ингибирующего топоизомеразу-i, нацеленного на trop-2 | |
| Conlin et al. | Taxanes in breast cancer: an update | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| KR102936318B1 (ko) | 소세포폐암의 병용 치료용 퀴놀린 유도체 | |
| Rodriguez‐Galindo et al. | Clinical use of topoisomerase I inhibitors in anticancer treatment | |
| Schöffski et al. | Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates | |
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| Dómine et al. | Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer | |
| Uranga et al. | Gastrointestinal side effects of anticancer therapy | |
| CN115397422A (zh) | 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途 | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| Conroy | Activity of vinorelbine in gastrointestinal cancers | |
| Mirimanoff | Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review | |
| Schiller | Role of taxanes in lung-cancer chemotherapy |